Yüklüyor......
Targeting the myostatin signaling pathway to treat muscle loss and metabolic dysfunction
Since the discovery of myostatin (MSTN; also known as GDF-8) as a critical regulator of skeletal muscle mass in 1997, there has been an extensive effort directed at understanding the cellular and physiological mechanisms underlying MSTN activity, with the long-term goal of developing strategies and...
Kaydedildi:
| Yayımlandı: | J Clin Invest |
|---|---|
| Yazar: | |
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
American Society for Clinical Investigation
2021
|
| Konular: | |
| Online Erişim: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8087205/ https://ncbi.nlm.nih.gov/pubmed/33938454 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1172/JCI148372 |
| Etiketler: |
Etiketle
Etiket eklenmemiş, İlk siz ekleyin!
|